Baker Avenue Asset Management’s Citius Pharmaceuticals CTXR Stock Holding History

Baker Avenue Asset Management’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-3,715	Closed	-$70K	–	256
2019 Q3	$70K	Buy	3,715 +320	+9%	+$8.44K	0.01%	237
2019 Q2	$83K	Hold	3,395	–	–	0.01%	234
2019 Q1	$120K	Buy	+3,395	New	+$99.9K	0.01%	239

Other funds holding CTXR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AWM

Argent Wealth Management Waltham, Massachusetts $602M AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Corbenic Partners Bethlehem, Pennsylvania $380M AUM 10.47% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Baker Avenue Asset Management's CTXR Position: Q4 2019 in Review

Baker Avenue Asset Management sold out of Citius Pharmaceuticals (CTXR) in Q4 2019, closing a stake of 3,715 shares — an estimated $70K sold.

Baker Avenue Asset Management first reported a position in CTXR in Q1 2019 and held it in 3 quarters. The position peaked at $120K in Q1 2019. 9 funds tracked by Wall St. Rank hold CTXR as of Q4 2019.

Baker Avenue Asset Management reported no remaining Citius Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Baker Avenue Asset Management sold 3,715 Citius Pharmaceuticals shares in Q4 2019, an estimated $70K.
Baker Avenue Asset Management first reported a position in Citius Pharmaceuticals in Q1 2019 and held it in 3 quarters.
Baker Avenue Asset Management's Citius Pharmaceuticals position peaked at $120K in Q1 2019.
9 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2019.

Based on Baker Avenue Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.